Faculty Information - SHINMURA Hiroaki

（Last updated : 2026-07-28 13:32:40）

SHINMURA Hiroaki
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2.	Other	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. 2026/05
3.	Other	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN. 2026/05
4.	Original article	Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
5.	Original article	Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
6.	Original article	Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
7.	Original article	Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
8.	Original article	Renal function with enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan. 2025/12
9.	Original article	Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
10.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
11.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
12.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
13.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
14.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
15.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
16.	Original article	Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma. 2025/01/03
17.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
18.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
19.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
20.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
21.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
22.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
23.	Original article	A single-center retrospective comparative analysis of urinary continence in robotic prostatectomy with a combination of umbilical ligament preservation and Hood technique. 2023/10
24.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
25.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/06
26.	Original article	An examination of the relationship between satisfaction with overactive bladder (OAB) treatment and the doctor–patient gender: A questionnaire-based single-institution study. 2023/03/25
27.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
28.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
29.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
30.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
31.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
32.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
33.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
34.	Original article	Assessment of understanding of urinary incontinence and its medical intervention in residents od a city affected by the Great East Japan Earthquake disaster 2017
35.	Original article	Whole body counter assessment of internal radiocontamination in patients with end-stage renal disease living in areas affected by the Fukushima Daiichi nuclear power plant disaster: a retrospective observational study. 2015/12
36.	Original article	Minimal internal radiation exposure in residents living south of the fukushima daiichi nuclear power plant disaster. 2015/10
37.	Original article	Whole-body counter surveys of over 2700 babies and small children in and around Fukushima Prefecture 33 to 49 months after the Fukushima Daiichi NPP accident. 2015/10
38.	Original article	Potential role of host effector memory CD8+ T cells in marrow rejection after mixed chimerism induction in cynomolgus monkeys 2010/08
39.	Case report	Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. 2010/02
40.	Original article	Analysis of Renal Transplant Protocol Biopsies in ABO-Incompatible Kidney Transplantation 2008/01
41.	Original article	Evaluation of Immunosuppressive Regimens in ABO-Incompatible Living Kidney Transplantation-Single Center Analysis 2007/04
Display 5 items
Display all(41)

■ Academic conference presentation

1.	Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in JAPAN. （ポスター掲示，一般） 2026/05/18
2.	Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in JAPAN （ポスター掲示，一般） 2026/05/16
3.	Real world data of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma: Multi-center retrospective study in Japan. （口頭，一般） 2026/04/24
4.	Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （ポスター掲示，一般） 2026/04/23
5.	Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （口頭，一般） 2026/04/23
6.	Novel peripheral blood immune clustering predicts prognosis and T cell exhaustion in renal cell carcinoma. （ポスター掲示，一般） 2026/04/23
7.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （ポスター掲示，一般） 2025/09/26
8.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （ポスター掲示，一般） 2025/04/28
9.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （ポスター掲示，一般） 2024/05/03
10.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （ポスター掲示） 2024/04/27
11.	Therapeutic efficacy of Cabozantinib or Axitinib rechallenge for advanced renal cell carcinoma. （ポスター掲示，一般） 2024/04/27
12.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （ポスター掲示） 2024/04/26
13.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （ポスター掲示，一般） 2024/04/26
14.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （ポスター掲示） 2024/04/26
15.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （ポスター掲示） 2024/04/26
16.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （ポスター掲示，一般） 2023/04/29
17.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （ポスター掲示，一般） 2023/04/29
18.	Retrospective comparative analysis of urinary incontinence in robotic prostatectomy with combination of umbilical ligament preservation and hood technique. （口頭，一般） 2023/04/22
19.	An examination of the relationship between satisfaction with overactive bladder treatment and the doctor-patient gender: a questionnaire-based study. （ポスター掲示，一般） 2023/04/20
20.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （口頭，一般） 2023/04/20
21.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （ポスター掲示，一般） 2022/05/13
22.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （ポスター掲示，一般） 2022/05/13
23.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （ポスター掲示，一般） 2022/05/13
24.	Impact of umbilical ligament preservation technique for robotic prostatectomy on urinary incontinence. 2020/12/22
25.	A case of hepatitis B virus transmission in kidney transplantation recipient from hepatitis B core antibody-positive and hepatitis B DNA-negative donor. （ポスター掲示，一般） 2019/09/15
26.	Long-term results of a case of ABO incompatible kidney transplantation with high titer of anti-ABO antibody using eculizumab induction. （口頭，一般） 2017/09/26
27.	Evaluation of the understanding of treatment for urinary incontinence in Iwaki city. （口頭，一般） 2017/04/22
28.	Excellent long-term outcome of kidney transplantation at a small local hospital, The TOKIWA-KAI foundation JYOBAN hospital in FUKUSHIMA. （ポスター掲示，一般） 2015/09/13
29.	Successful ABO-blood group incompatible kidney transplantation under eculizumab induction. （ポスター掲示，一般） 2015/09/13
30.	A case of hepatitis B virus transmission in kidney transplantation recipient from hepatitis B core antibody-positive and hepatitis B DNA-negative donor. （ポスター掲示，一般） 2015/08/26
31.	A successful case of ABO incompatible kidney transplantation with high anti-blood type antibody titer using eculizumab induction protocol. （ポスター掲示，一般） 2015/08/25
32.	Supporting activity for retroperitoneoscopic living-donor nephrectomy in JAKARTA hospital from JAPAN. （ポスター掲示，一般） 2015/08/24
33.	An Open Label, Prospecive Randomized Controlled Study Comparing Tacrolimus Once-Daily and Twice-Daily in De Novo Kidney Transplatation: Pharmacokinetics and Pathological Analysis by Protocol Biopsy （口頭，一般） 2012/06/03
Display 5 items
Display all(33)

■ Social activities

2018/04

Fukushima doctor visits elderly patients dressed as period drama characters

■ Education

1.	2001/04～2005/03	〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed,
2.	1986/04～1993/03	Graduate School, Division of Medicine, Toyama Medical and Pharmaceutical University, Graduated,